Neuropathic Pain

Sativex Phase III Trial in MS Neuropathic Pain Completes Patient Recruitment

Published in Pain and Central Nervous System Week, September 17th, 2007

GW Pharmaceuticals plc (AIM: GWP) announces that patient recruitment is now complete in its pivotal Phase III trial in people with multiple sclerosis (MS) suffering from central neuropathic pain.

This Phase III study is a double-blind randomised placebo-controlled study of Sativex(R) in patients with central neuropathic pain due to MS, who have achieved inadequate pain relief with existing therapies. The study has recruited 339 patients in the UK, Canada, France, Spain and the Czech Republic and is GW's largest clinical trial to date.

The duration of treatment in the study is 14 weeks. The last patient will exit the study at the end of 2007 with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2007-09-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry